| Title: | Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers |
| Journal: | Leukemia |
| Published: | 14 Apr 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41981103/ |
| DOI: | https://doi.org/10.1038/s41375-026-02946-x |
Publication 17999
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an elevated risk of hematologic and solid cancers. We performed a prospective cohort study, including 63690 patients with a first diagnosis of primary cancer in the UK Biobank during 2006 to 2022, to investigate the association of pre-diagnostic CHIP with future risk of second cancers. Cox regression was employed to assess the association between pre-diagnostic CHIP and risk of developing second cancer among patients with primary cancer. We identified 2860 patients with and 60626 without pre-diagnostic CHIP. During a median follow-up of 3.9 years, patients with primary cancer with pre-diagnostic CHIP experienced a greater risk of any second cancer (hazard ratio 1.3, 95% confidence intervals 1.2-1.5), compared with those without pre-diagnostic CHIP. Increased risk of any second cancer was mainly noted for patients with pre-diagnostic CHIP and primary myelodysplastic neoplasia, myeloproliferative neoplasms, non-Hodgkin lymphoma, or breast cancer. Regarding types of outcome (i.e., second cancer), the excess risk was particularly high for second myeloid malignancy and non-myeloid hematological malignancy. The risk for a second cancer was mainly observed in DNMT3A-, TET2-, SRSF2-, or JAK2-mutant CHIP. These findings suggest increased awareness of second cancer risk among patients with primary cancer and pre-diagnostic CHIP.</p>
7 Authors
- Xinyuan Liu
- Hans-Olov Adami
- Erik Boberg
- Karin E. Smedby
- Hui Wei
- Fang Fang
- Qianwei Liu
1 Application
| Application ID | Title |
|---|---|
| 106912 | Comprehensive investigation of biomarkers and medical conditions in relation to subsequent hematological disorders or cancer |
Enabling scientific discoveries that improve human health